Semax is a synthetic heptapeptide derived from ACTH(4–7) extended with a Pro-Gly-Pro sequence for enhanced stability. Approved as a pharmaceutical in Russia for stroke rehabilitation and cognitive impairment. Primary mechanism: rapid and potent BDNF and NGF upregulation in the hippocampus, prefrontal cortex, and limbic regions.
- BDNF and NGF upregulation — rapidly increases BDNF and NGF in hippocampus and frontal cortex, supporting neuroplasticity.
- Cognitive and learning enhancement — improved spatial learning and memory retention in animal models via TrkB/BDNF signalling.
- Neuroprotection in injury models — reduces infarct size and neuronal apoptosis in ischaemic stroke models.
- Dopaminergic and serotonergic modulation — influences receptor density in limbic structures relevant to attention and motivation.
- Approved clinical track record — registered pharmaceutical in Russia for stroke and memory/attention disorders.
⚠️ For research use only. Not for human or animal consumption. Store at −20°C. Reconstitute with Bacteriostatic Water.



Reviews
There are no reviews yet.